Search Results
Nov 24, 2025, 13:29 ET U.S. Software as a Medical Device Market to Reach USD 715 Million by 2033 as AI-Driven Diagnostics and Digital Therapeutics Accelerate Adoption
Device tools for COPD monitoring, asthma management, and sleep disorder detection are expanding rapidly due to the increasing prevalence of chronic lung diseases.Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer):
More news about: DataM Intelligence 4 Market Research LLP
Nov 24, 2025, 07:30 ET Shapeshifting cancers' masters, unmasked
like skin cells. Meanwhile, in Cell Reports, they uncover the crystal structure of another group of proteins that plays a key role in tuft cell lung cancer.This latest finding represents a full-circle moment for the lab, Vakoc explains. When he and his colleagues
More news about: Cold Spring Harbor Laboratory
Nov 24, 2025, 07:00 ET Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer
(quaratusugene ozeplasmid) in combination with Tagrisso® (osimertinib) in patients with advanced non-small cell lung cancer (NSCLC) in the peer-reviewed journal Clinical Lung Cancer.
More news about: Genprex, Inc.
Nov 24, 2025, 07:00 ET Kelun-Biotech Announces Phase III Trial of Sac-TMT in Combination with KEYTRUDA® (pembrolizumab) as First-Line Treatment for PD-L1-Positive NSCLC Met Primary Endpoint
III clinical study (OptiTROP-Lung05) of the company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870), in combination with MSD's anti-PD-1 therapy KEYTRUDA®[1] (pembrolizumab), as a first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC),
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nov 24, 2025, 07:00 ET Galvanize Therapeutics Appoints Laura Francis to its Board of Directors
("Galvanize") Therapeutics, Inc., a commercial-stage medical technology company pioneering pulsed electric field (PEF) therapies for oncology and chronic lung disease, today announced the appointment of Laura Francis to its Board of Directors. An experienced medical technology executive, Francis is
More news about: Galvanize Therapeutics, Inc.
Nov 24, 2025, 05:19 ET Drs. Elliott Brea, Esther Redin, and Gavitt Woodard Announced as Recipients of LUNGevity's Career Development Awards
entry into lung tumors, and its relationship with common lung cancer mutations. The goal of this work is to understand and improve T cell activity in lung tumors to make immunotherapy more effective."Making immunotherapy more effective for the hundreds of thousands of people living with lung cancer
More news about: LUNGevity Foundation
Nov 24, 2025, 03:55 ET Mercuria Successfully Closes USD 2.3 Billion Equivalent Asian Revolving Credit Facilities
Corporation Limited Shanghai Branch, China CITIC Bank International Limited Singapore Branch, China Merchants Bank Co. Ltd. Singapore Branch, CMB Wing Lung Bank Limited, DBS Bank Ltd., Industrial and Commercial Bank of China Limited London Branch, Mizuho Bank Ltd., MUFG Bank Ltd., Oversea-Chinese Banking
More news about: Mercuria Energy
Nov 21, 2025, 10:08 ET TVRD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics
clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company
More news about: Faruqi & Faruqi, LLP
Nov 21, 2025, 01:00 ET aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR
that, "aTyr Pharma said on Monday its experimental drug had failed to meet the main goal in a late-stage study testing it in patients with a type of lung disease known as pulmonary sarcoidosis, which impacts the lungs and lymph nodes." Based on this news, shares of aTyr traded down by more than 81% in
More news about: DJS Law Group LLP
Nov 20, 2025, 20:00 ET Fosun International Honored as "ESG Leading Enterprise" by Bloomberg Businessweek/Chinese Edition
monoclonal antibody independently developed by Fosun, is the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). It has been approved for marketing in nearly 40 countries and regions, including China, the European Union, the United Kingdom, Singapore,
More news about: Fosun
Nov 20, 2025, 10:30 ET Radiology AI Market worth $2.27 billion by 2030 with 24.5% CAGR | MarketsandMarkets™
detection, automating tumor segmentation and quantification, and enhancing therapy response evaluation. High imaging volume in cancers such as breast, lung, prostate, and colorectal further accelerates adoption. Additionally, oncology-focused AI solutions benefit from strong regulatory momentum, growing
More news about: MarketsandMarkets
Nov 20, 2025, 09:02 ET Late-Stage Lung Cancer Diagnoses Plummet to a New Low in the Bronx
survival rates. Early detection enables 95% of lung cancer operations at Montefiore Einstein to be performed with minimally invasive "lung sparing" techniques. This allows greater preservation of normal lung function so Bronx residents can return to enjoying full lives post-cancer treatment.
More news about: Montefiore Einstein Comprehensive Cancer Center
Nov 20, 2025, 09:00 ET Co-Diagnostics Delivers Address about Tuberculosis Test Adoption and Implementation at The Union World Conference on Lung Health
Business Development, Joseph Featherstone, addressed a satellite session of the International Union Against Tuberculosis and Lung Disease (The Union) 2025 World Conference on Lung Health earlier today in Copenhagen, Denmark, in a talk providing industry perspective on adoption and implementation of a tuberculosis
More news about: Co-Diagnostics
Nov 20, 2025, 08:03 ET Mercy Halo Blood Test Shows Promise in Early Lung Cancer Detection: New Study Shows Performance Similar to LDCT with Clinical Complementarity
data from a groundbreaking study leveraging samples from the National Lung Screening Trial (NLST). The study results suggest that the Mercy Halo blood-based lung screening test may significantly enhance early-stage preclinical lung cancer detection, particularly among individuals at elevated risk who
More news about: Mercy BioAnalytics
Nov 20, 2025, 07:30 ET Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
screening Cancerguard detects 50 cancer types, even the most aggressive – such as pancreatic, ovarian, liver, esophageal, lung and stomach – through a simple blood draw Oncoguard Liver Test finds the most common liver cancer in people with cirrhosis
More news about: Abbott
Nov 20, 2025, 07:00 ET Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion (ex20ins) mutations who have previously received platinum-based systemic chemotherapy.
More news about: Taiho Oncology
Nov 20, 2025, 05:03 ET LUNGevity Invests in Lung Cancer Workforce Expansion Through Four Strategic Research Awards
million in lung cancer research over the past two decades. With these 2025 research awards, LUNGevity continues their longstanding commitment to cultivating the scientific workforce and advancing high-impact lung cancer research. "It is imperative that we build a vibrant lung cancer
More news about: LUNGevity Foundation
Nov 20, 2025, 00:01 ET Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research
Immunotherapy of Cancer (SITC): Study demonstrated how AI-based spatial profiling and machine learning can identify immune-active subtypes of non-small cell lung cancer (NSCLC) tumors with the MET exon 14 skipping mutation, which are associated with improved immunotherapy outcomes. Using Lunit SCOPE IO®,
More news about: Lunit
Nov 19, 2025, 21:56 ET Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
reported no safety issues despite having been on the treatment for more than two years. In the subgroup of patients with CPI-resistant non-small cell lung cancer (14 patients), the ORR was 21.4%, the DCR was 71.4%, including 3 PRs. These findings suggest that ATG-037 has clinically meaningful therapeutic
More news about: Antengene Corporation Limited
Nov 19, 2025, 16:19 ET Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC
zidesamtinib, an investigational ROS1-selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least 1 prior ROS1 tyrosine kinase inhibitor (TKI). The application has been assigned a Prescription Drug User Fee Act
More news about: Nuvalent, Inc.
Nov 19, 2025, 16:05 ET PIH Health Now Offering Innovative Zephyr® Endobronchial Valve Procedure for Patients with Severe COPD and Emphysema
valves into the most damaged areas of the lung, we can redirect airflow to the healthier lobes, helping patients breathe more comfortably without the need for major surgery or a lung transplant." Previously, patients with these advanced lung conditions often had limited treatment
More news about: PIH Health
Nov 19, 2025, 16:01 ET FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
lines of therapy for small cell lung cancer patients." "For far too long, people living with small cell lung cancer had few options once their first treatment stopped working," said Laurie Fenton Ambrose, co-founder, president, and CEO, GO2 for Lung Cancer. "Today's full approval
More news about: Amgen
Nov 19, 2025, 15:30 ET With a $2.5B Valuation, Function Becomes the New Standard for Health and Launches Medical Intelligence Lab
accessible to more people. The advanced MRI can detect cancers, unruptured aneurysms, endometriosis, signs of stroke, etc., while the CT scan can identify lung cancer, plaque in the heart, etc. All data is integrated into a single intelligent interface, giving each member a personalized view of their health
More news about: Function Health
Nov 19, 2025, 13:27 ET Wellcare Enhances Offering of Affordable, Quality Medicare Advantage and Medicare Prescription Drug Plans in 2026
must have one or more of the following chronic conditions: cancer, cardiovascular disorders, chronic and disabling mental health conditions, chronic lung disorders, diabetes. There are other eligible conditions not listed. Eligibility for this benefit cannot be guaranteed based solely on your condition.
More news about: Wellcare
Nov 19, 2025, 12:07 ET Latest ACS Lung Cancer Data: Only 1 in 5 Eligible Adults in U.S. Screened for Lung Cancer; 62,000 Lives Over 5 Years Could be Saved if All Eligible Screened
more lung cancer deaths could be prevented (or lives saved) if everyone eligible were screened." Lung cancer is the second most common cancer in the U.S., with around 225,000 new cases diagnosed in 2025, and the leading cause of cancer death, with 125,000 deaths from lung cancer
More news about: American Cancer Society